We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

18 hedge funds and large institutions have $1.14M invested in Titan Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

205% more capital invested

Capital invested by funds: $374K → $1.14M (+$765K)

0.11% more ownership

Funds ownership: 0.25% → 0.36% (+0.11%)

5% less funds holding

Funds holding: 19 → 18 (-1)

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

Holders
18
Holders Change
-1
Holders Change %
-5.26%
% of All Funds
0.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
4
Closed
5
Calls
$45K
Puts
–
Net Calls
+$45K
Net Calls Change
+$39K

Top Buyers

Rank Fund Capital Flow
1
Truist Financial
Truist Financial
North Carolina
+$807K
2
State Street
State Street
Massachusetts
+$49.4K
3
FIA
FNY Investment Advisers
New York
+$36.2K
4
Citadel Advisors
Citadel Advisors
Florida
+$16.9K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$9.06K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$124K
2
Millennium Management
Millennium Management
New York
-$58.9K
3
VF
Virtu Financial
New York
-$43.9K
4
Group One Trading
Group One Trading
Illinois
-$33K
5
HF
HRT Financial
New York
-$29K
Name Holding Trade Value Shares
Change 		Change in
Stake
Truist Financial
1
Truist Financial
North Carolina
$675K +$807K +31,254 New
Renaissance Technologies
2
Renaissance Technologies
New York
$156K -$124K -4,800 -40%
Vanguard Group
3
Vanguard Group
Pennsylvania
$88K +$9.06K +351 +9%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$69K +$2.25K +87 +3%
State Street
5
State Street
Massachusetts
$41K +$49.4K +1,914 New
VF
6
Virtu Financial
New York
$31K -$43.9K -1,700 -55%
FIA
7
FNY Investment Advisers
New York
$30K +$36.2K +1,401 New
Millennium Management
8
Millennium Management
New York
$19K -$58.9K -2,282 -72%
Citadel Advisors
9
Citadel Advisors
Florida
$14K +$16.9K +654 New
UBS Group
10
UBS Group
Switzerland
$12K -$20.3K -788 -59%
IA
11
IFP Advisors
Florida
$3K – – –
LFA
12
Level Financial Advisors
New York
$1K – – –
APA
13
American Portfolios Advisors
New York
$25 – – –
Group One Trading
14
Group One Trading
Illinois
– -$33K -2,975 Closed
HF
15
HRT Financial
New York
– -$29K -2,605 Closed
E
16
Ergoteles
New York
– -$11K -949 Closed
Citigroup
17
Citigroup
New York
– -$1K -88 Closed
Simplex Trading
18
Simplex Trading
Illinois
– -$620 -24 Closed
Morgan Stanley
19
Morgan Stanley
New York
– +$26 +1 +100%

TTNP Hedge Fund Activity: Q3 2022 in Review

18 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q3 2022, worth a combined $1.14M — up 205% from $374K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of TTNP and 4 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 3 added.

The largest buyer was Truist Financial, opening a new position worth an estimated $807K. The largest seller was Renaissance Technologies, cutting an estimated $124K.

  • 18 institutional investors held Titan Pharmaceuticals (TTNP) as of Q3 2022, down from 19 in Q2 2022.
  • Funds reported $1.14M of Titan Pharmaceuticals stock for Q3 2022, up 205% quarter-over-quarter.
  • 4 funds opened new Titan Pharmaceuticals positions in Q3 2022 and 5 closed out, a net change of -1 holder.
  • The largest Titan Pharmaceuticals buyer in Q3 2022 was Truist Financial, an estimated $807K added.
  • The largest Titan Pharmaceuticals seller in Q3 2022 was Renaissance Technologies, an estimated $124K sold.

Based on aggregated 13F filings for Q3 2022.